Print

Purpose

Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.

Condition

Eligibility

Eligible Ages
Over 22 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. ≥ 22 years of age. 2. Have migraine onset at ≤ 50 years of age. 3. Have a history of migraine for ≥ 12 months prior to screening. 4. Have 15 - 26 headache days/month, among which ≥ 8 days has the features of probable migraine, and minimum of 2 headache-free days/month during the 28-day screening period. 5. Fulfill the criteria for chronic migraine (CM) during the 28-day screening period. 6. Have a diagnosis of refractory chronic migraine (RCM), who have inadequate response or no access to, or are intolerant, unwilling, or contraindicated to Onabotulinum toxin A (Botox) therapy, and One of the medications that belong to Calcitonin Gene Related Peptide Monoclonal antibodies (CGRP) therapy or CGRP antagonist therapy. 7. Maintain a stable use of preventive(s) migraine medication for ≥ 3 months before screening. 8. Demonstrate ≥ 80% compliance with the headache diary during the screening period by entering headache data on a minimum of 22 out of 28 days. 9. Be willing and able to comply with all study procedures and return to the clinic for the follow-up evaluation, as specified in this protocol. 10. Be able to give voluntary, written informed consent to participate in this study.

Exclusion Criteria

  1. Type of headache or migraine other than RCM including the following: 1. Post-traumatic headache (e.g., battlefield, accidents, etc.). 2. Regular intake of opioids (including codeine) of ≥ 8 days in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis. 3. Regular intake of Barbiturates for ≥ 5 days/month in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis. 4. Report experiencing unremitting, continuous headaches with no relief. 5. Have new daily persistent headache (NDPH) defined by iCHD-3 as persistent headache, daily from its onset, which is clearly remembered. The pain lacks characteristic features and may be migraine-like or tension-type like or have elements of both with a CM subtype. 2. History of treatments that could confound the results of the study 1. Previously implanted neurostimulator to stimulate the greater occipital and/or supraorbital nerves to treat headache. 2. Have received onabotulinumtoxinA (Botox) for any other medical or cosmetic reasons requiring injections in the head, face, or neck within 6 months prior to screening. 3. Have had any cervical radiofrequency ablation within 12 months. 4. Subjects with recent brain or facial trauma occurring less than 3 months prior to the Baseline Visit. 5. Subjects that may have received sequential multi-day in-patient parenteral infusion for the treatment of a migraine condition (e.g., status migrainosus) within the previous 2 weeks of the initiation of diary screening phase. 6. Subject has other implanted electrical stimulation device(s) or any metallic implant (excluding dental implants) including: 1. Cardiac pacemakers or defibrillators 2. Cochlear implant 3. CSF shunt 4. Surgical clip (above the shoulder line) 5. Intrathecal pumps 6. Spinal cord stimulator 7. Use of nerve blocks, acupuncture, neurostimulation and/or transcranial magnetic stimulation) for migraine within 3 months prior to screening and after receiving implant system. 8. Any pre-existing or requirement of emergent surgery/procedure that may interfere or confound the results of the study. 9. Any known requirement for an MRI scan subsequent to implant of the neurostimulator. 10. Current or history of following comorbidities: 1. Clinically significant psychiatric illnesses, including suicide attempt, or suicidal ideation with a specific plan in the past 2 years. 2. Cancer in the past 5 years, except for appropriately treated nonmelanoma skin carcinoma. 3. Have a current diagnosis or condition that presents excess risk for performing the procedure, as determined clinically by the Investigator. 4. Substance use disorder of at least moderate severe for substances such as; alcohol, recreational marijuana, or illicit drugs during the past 2 years. 11. Unable to participate or successfully complete the study, in the opinion of the investigator. 12. Anatomy not suitable for placement of the study device. 13. Are currently a study center or Sponsor employee who is directly involved in the study or the relative of such an employee. 14. Pregnant or lactating female or planning a pregnancy during participation in the study. 15. Patient with life expectancy of less than 1.5 years. 16. Currently participating in or planning to participate in other investigational drug or device studies that may interfere or confound the results of the study.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
High Dose
  • Device: Neurostimulator
    Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.
Sham Comparator
Low Dose
  • Device: Neurostimulator
    Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.

Recruiting Locations

Neurovations
Napa, California 94558
Contact:
707-252-9606

Barolat Neuroscience
Denver, Colorado 80218
Contact:
303-865-7800

Vista Clinical Research and Summit Spine & Joint
Newnan, Georgia 30265
Contact:
770-755-6914

iSpine Clinics
Chaska, Minnesota 55318
Contact:
763-201-8191

Mayo Clinic Rochester
Rochester, Minnesota 55905
Contact:
507-422-0584

Dent Neurologic Institute
Amherst, New York 14226
Contact:
715-558-5670

Northwell Health Physician Partners
New York, New York 10019
Contact:
646-370-7221

Queen City Clinical Research
Charlotte, North Carolina 28211
Contact:
704-405-3150

The Center for Clinical Research
Winston-Salem, North Carolina 27103
Contact:
366-714-8388

Argires Marotti Neurological Associates
Lancaster, Pennsylvania 17601
Contact:
717-799-3270

More Details

NCT ID
NCT06167655
Status
Recruiting
Sponsor
ShiraTronics

Study Contact

Ecklund
1-844-228-7330
fecklund@shiratronics.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.